Zafirlukast has no beneficial effects in the treatment of chronic urticaria

Clinical and Experimental Allergy

Volumn 32, Issue 12, 2002, Pages 1763-1768

  Reimers, Andrea ^a   Pichler, C ^b   Helbling, A ^b   Pichler, W J ^b   Yawalkar, N ^c  

^a Medical Division   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c Harvard Skin Disease Research Center   (United States)

Author keywords

Chronic urticaria; Leukotriene receptor antagonist; Zafirlukast

Indexed keywords

ACRIVASTINE; IMMUNOGLOBULIN E; ZAFIRLUKAST; DRUG DERIVATIVE; HISTAMINE H1 RECEPTOR ANTAGONIST; LEUKOTRIENE RECEPTOR BLOCKING AGENT; TOLUENESULFONIC ACID DERIVATIVE; TRIPROLIDINE;

ADULT; AGED; ARTICLE; CHRONIC URTICARIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TOLERANCE; EVALUATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPTOM; UNIVERSITY HOSPITAL; ADOLESCENT; CHRONIC DISEASE; DRUG ADMINISTRATION; MIDDLE AGED; TREATMENT OUTCOME; URTICARIA;

ADOLESCENT; ADULT; AGED; CHRONIC DISEASE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HISTAMINE H1 ANTAGONISTS; HUMANS; LEUKOTRIENE ANTAGONISTS; MALE; MIDDLE AGED; TOSYL COMPOUNDS; TREATMENT OUTCOME; TRIPROLIDINE; URTICARIA;

EID: 0036456830     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2222.2002.01536.x     Document Type: Article

References (26)

1. Greaves MW. Chronic urticaria. N Engl J Med 1995; 332:1767-72.
2. Greaves M. Chronic urticaria. J Allergy Clin Immunol 2000; 105:664-72.
3. O'Donnell BF, Lawlor F, Simpson J, Morgan M, Greaves MW. The impact of chronic urticaria on the quality of life. Br J Dermatol 1997; 136:197-201.
4. Wanderer AA, Bernstein LI, Goodman DL et al. The diagnosis and management of urticaria. Ann Allergy Asthma Immunol 2000; 85:521-44.
5. Ellis MH. Successful treatment of chronic urticaria with leukotriene antagonists. J Allergy Clin Immunol 1998; 102:876-7.
6. Spector S, Tan RA. Antileukotrienes in chronic urticaria. J Allergy Clin Immunol 1998; 101:572.
7. Asero R. Leukotriene receptor antagonists may prevent NSAID-induced exacerbations in patients with chronic urticaria. Ann Allergy Asthma Immunol 2000; 85:156-7.
8. Berkun Y, Shalit M. Successful treatment of delayed pressure urticaria with montelukast. Allergy 2000; 55:203-4.
9. Hani N, Hartmann K, Casper C et al. Improvement of cold urticaria by treatment with the leukotriene receptor antagonist montelukast. Acta Derm Venereol 2000; 80:229.
10. Tedeschi A, Suli C, Lorini M, Airaghi L. Successful treatment of chronic urticaria. Allergy 2000; 55:1097-8.
11. Bensch G, Borish L. Leukotriene modifiers in chronic urticaria. Ann Allergy Asthma Immunol 1999; 83:348.
12. Chu TJ, Warren MS. Zafirlukast in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol 1998; 101:155.
13. Norris GJ, Sullivan TJ. Leukotrienes and cytokines in steroid dependent chronic urticaria. J Allergy Clin Immunol 1998; 101:128.
14. Pacor ML, Di Lorenzo G, Corrocher R. Efficacy of leukotriene receptor antagonist in chronic urticaria. A double-blind, placebo-controlled comparison of treatment with montelukast and cetirizine in patients with chronic urticaria with intolerance to food additive and/or acetylsalicylic acid. Clin Exp Allergy 2001; 31:1607-14.
15. Nettis E, Dambra P, D'Oronzio L, Loria MP, Ferrannini A, Tursi A. Comparison of montelukast and fexofenadine for chronic idiopathic urticaria. Arch Dermatol 2001; 137:99-100.
16. Wedi B, Novacovic V, Koerner M, Kapp A. Chronic urticaria serum induces histamine release, leukotriene production and basophil CD63 surface expression-inhibitory effects of anti-inflammatory drugs. J Allergy Clin Immunol 2000; 105 (3):552-60.
17. Maxwell DL, Atkinson BA, Spur BW, Lessof MH, Lee TH. Skin responses to intradermal histamine and leukotrienes C4, D4 and E4 in patients with chronic urticaria and in normal subjects. J Allergy Clin Immunol 1990; 86:759-65.
18. Ohnishi-Inoue Y, Mitsuya K, Horio T. Aspirin-sensitive urticaria: Provocation with a leukotriene receptor antagonist. Br J Dermatol 1998; 138:483-5.
19. Adkins JC, Brogden RN. Zafirlukast: A review of its pharmacological and therapeutic potential in the management of asthma. Drugs 1998; 1:121-44.
20. Senn S. Cross-Over Trials in Clinical Research. New York: John Wiley, 1993.
21. Greaves MW, Sabroe RA. ABC of allergies: Allergy and the skin. I. Urticaria. Br Med J 1998; 316:1147-50.
22. Henz BM, Zuberbier T. Urtikaria. Hautarzt 2000; 51:302-8.
23. Juhlin L. Recurrent urticaria: Clinical investigation of 330 patients. Br J Dermatol 1981; 104:369-81.
24. Humphreys F, Hunter JA. The characteristics of urticaria in 390 patients. Br J Dermatol 1998; 138:635-8.
25. Champion RH, Roberts SO, Carpenter RG, Roger JH. Urticaria and angio-oedema. Br J Dermatol 1969; 81:588-97.
26. Dahlen B, Nizankowsk E, Szczeklik A et al. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin intolerant asthma. Am J Crit Care Med 1998; 157:1187-94.